This rapid and increasing uptake underscores the potential of LAMP1-based radiopharmaceuticals for imaging and therapeutic applications across a spectrum of human carcinomas, such as colon, breast, and prostate cancers [19]. This evidence concerns the gene LAMP1 and Familial prostate cancer.